FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553634948> ?p ?o ?g. }

• W2553634948 endingPage "66" @default.
• W2553634948 startingPage "59" @default.
• W2553634948 abstract "The main goal of this study was to analyse whether initial addition of glucocorticoid to DMARD therapy influences the long-term course of the disease in patients with early rheumatoid arthritis. All patients from the Swiss RA cohort SCQM with recent-onset arthritis (disease duration ≤1 year) were analysed. The exposure of interest was the use of glucocorticoids (GCs) at baseline. As primary outcome, we considered clinical and radiographic disease progression, assessed by the disease activity (disease activity score, DAS-28), function (health assessment questionnaire disability index, HAQ-DI) and structural joint damage (Ratingen erosion score). The baseline disease characteristics were compared using standard descriptive statistics. The effects of initial GC use on disease progression during follow-up were estimated using linear mixed models with random slope and random intercept, adjusted for potential confounders. In total, 592 patients with early disease were available, with 4.3 years of follow-up (average). Of these, 363 were initially treated with glucocorticoids (GC patients) and 228 were not (no-GC patients). DAS-28 (4.6 vs. 4.3, p = 0.01) and the HAQ-DI (0.94 vs. 0.82, p = 0.01) were higher at baseline in GC patients, while other prognostic factors were balanced at baseline. Neither the change of DAS-28, of HAQ-DI nor of the development of joint erosions differed between the two groups during follow-up. Escalation of treatment employing biologics was documented in 18.0% of the no-GC patients and 27.3% of the GC patients (p < 0.01). In this cohort, patients with early RA initially treated with GCs had higher measures of disease activity at baseline in comparison to no-GC patients. Despite a similar course of the disease in GC versus non-GC patients, the higher escalation rate to biologic agents in GC patients may reflect a disease less responsive to therapy in these patients. These data suggest that GC use as part of the initial therapeutic strategy in early RA may prevent a more severe course of the disease in patients with higher clinical disease measures at the start of therapy." @default.
• W2553634948 created "2016-11-30" @default.
• W2553634948 creator A5009471725 @default.
• W2553634948 creator A5018044317 @default.
• W2553634948 creator A5020220564 @default.
• W2553634948 creator A5024382094 @default.
• W2553634948 creator A5046411034 @default.
• W2553634948 creator A5047233668 @default.
• W2553634948 creator A5068008759 @default.
• W2553634948 creator A5078028036 @default.
• W2553634948 creator A5079051965 @default.
• W2553634948 creator A5087327704 @default.
• W2553634948 date "2016-11-12" @default.
• W2553634948 modified "2023-10-14" @default.
• W2553634948 title "Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)" @default.
• W2553634948 cites W125376064 @default.
• W2553634948 cites W1821977962 @default.
• W2553634948 cites W1967672301 @default.
• W2553634948 cites W1982176411 @default.
• W2553634948 cites W1994955363 @default.
• W2553634948 cites W2027049305 @default.
• W2553634948 cites W2028764755 @default.
• W2553634948 cites W2037939754 @default.
• W2553634948 cites W2049427951 @default.
• W2553634948 cites W2051552760 @default.
• W2553634948 cites W2053939665 @default.
• W2553634948 cites W2080638211 @default.
• W2553634948 cites W2084911737 @default.
• W2553634948 cites W2105500082 @default.
• W2553634948 cites W2114229314 @default.
• W2553634948 cites W2115068422 @default.
• W2553634948 cites W2120393706 @default.
• W2553634948 cites W2122641956 @default.
• W2553634948 cites W2139112490 @default.
• W2553634948 cites W2152178646 @default.
• W2553634948 cites W2155195115 @default.
• W2553634948 cites W2156996668 @default.
• W2553634948 cites W2163771807 @default.
• W2553634948 cites W2171573452 @default.
• W2553634948 cites W2323601729 @default.
• W2553634948 cites W2340461942 @default.
• W2553634948 cites W4210768724 @default.
• W2553634948 cites W44457900 @default.
• W2553634948 doi "https://doi.org/10.1007/s10067-016-3468-6" @default.
• W2553634948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27838788" @default.
• W2553634948 hasPublicationYear "2016" @default.
• W2553634948 type Work @default.
• W2553634948 sameAs 2553634948 @default.
• W2553634948 citedByCount "12" @default.
• W2553634948 countsByYear W25536349482017 @default.
• W2553634948 countsByYear W25536349482019 @default.
• W2553634948 countsByYear W25536349482020 @default.
• W2553634948 countsByYear W25536349482021 @default.
• W2553634948 countsByYear W25536349482022 @default.
• W2553634948 crossrefType "journal-article" @default.
• W2553634948 hasAuthorship W2553634948A5009471725 @default.
• W2553634948 hasAuthorship W2553634948A5018044317 @default.
• W2553634948 hasAuthorship W2553634948A5020220564 @default.
• W2553634948 hasAuthorship W2553634948A5024382094 @default.
• W2553634948 hasAuthorship W2553634948A5046411034 @default.
• W2553634948 hasAuthorship W2553634948A5047233668 @default.
• W2553634948 hasAuthorship W2553634948A5068008759 @default.
• W2553634948 hasAuthorship W2553634948A5078028036 @default.
• W2553634948 hasAuthorship W2553634948A5079051965 @default.
• W2553634948 hasAuthorship W2553634948A5087327704 @default.
• W2553634948 hasBestOaLocation W25536349482 @default.
• W2553634948 hasConcept C126322002 @default.
• W2553634948 hasConcept C1862650 @default.
• W2553634948 hasConcept C188816634 @default.
• W2553634948 hasConcept C198451711 @default.
• W2553634948 hasConcept C201903717 @default.
• W2553634948 hasConcept C23131810 @default.
• W2553634948 hasConcept C2777575956 @default.
• W2553634948 hasConcept C2779134260 @default.
• W2553634948 hasConcept C71924100 @default.
• W2553634948 hasConcept C72563966 @default.
• W2553634948 hasConcept C77350462 @default.
• W2553634948 hasConceptScore W2553634948C126322002 @default.
• W2553634948 hasConceptScore W2553634948C1862650 @default.
• W2553634948 hasConceptScore W2553634948C188816634 @default.
• W2553634948 hasConceptScore W2553634948C198451711 @default.
• W2553634948 hasConceptScore W2553634948C201903717 @default.
• W2553634948 hasConceptScore W2553634948C23131810 @default.
• W2553634948 hasConceptScore W2553634948C2777575956 @default.
• W2553634948 hasConceptScore W2553634948C2779134260 @default.
• W2553634948 hasConceptScore W2553634948C71924100 @default.
• W2553634948 hasConceptScore W2553634948C72563966 @default.
• W2553634948 hasConceptScore W2553634948C77350462 @default.
• W2553634948 hasIssue "1" @default.
• W2553634948 hasLocation W25536349481 @default.
• W2553634948 hasLocation W25536349482 @default.
• W2553634948 hasLocation W25536349483 @default.
• W2553634948 hasOpenAccess W2553634948 @default.
• W2553634948 hasPrimaryLocation W25536349481 @default.
• W2553634948 hasRelatedWork W2137023321 @default.
• W2553634948 hasRelatedWork W2139524779 @default.
• W2553634948 hasRelatedWork W22615656 @default.
• W2553634948 hasRelatedWork W2774333488 @default.

• next